Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma

Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma

Asthma is a heterogeneous chronic disease of airways. One of its endotypes is eosinophilic asthma, accompanied by both peripheral blood and airway eosinophilia, where severe eosinophilia is usually associated with more severe asthma. Anti - interleukin-5 (IL-5) monoclonal antibodies (MAb) can reduce...

Full description

Bibliographic Details
Main Authors: A S Kolbin, S N Avdeev, M V Zhuravleva, Yu M Gomon, Yu E Balykina, N V Matveyev, M A Proskurin, S V Fedosenko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2019-12-01
Series:Терапевтический архив
Subjects:
pharmacoeconomics
reslizumab
omalizumab
severe eosinophilic asthma
budget impact analysis
cost effectiveness analysis
monoclonal antibodies
interleukin-5
direct costs
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/33739/pdf

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/33739/pdf

Similar Items